News Releases | Lexicon Pharmaceuticals, Inc.

Press Releases

Lexicon Pharmaceuticals Announces Topline Phase 3 Data from Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes	Jul 21, 2020
Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference	Jul 20, 2020
Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions	Jun 13, 2020
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	May 27, 2020
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines	May 13, 2020
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update	Apr 27, 2020
Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast on April 27, 2020	Apr 22, 2020
Lexicon Pharmaceuticals to Host Virtual Annual Meeting of Stockholders on April 23, 2020	Apr 07, 2020
Lexicon Pharmaceuticals Provides an Update on the Sotagliflozin Type 2 Diabetes Program	Mar 19, 2020
Lexicon Pharmaceuticals Announces Additional Data on Telotristat Ethyl’s Antiproliferative Effects in Patients with Carcinoid Syndrome	Mar 13, 2020